NGC Update Service: December 9, 2013

National Guideline Clearinghouse (NGC)

December 9, 2013


New This Week

Guideline Summaries

Congress of Neurological Surgeons

Withdrawn Summaries

These summaries have been withdrawn from the NGC Web site because they no longer meet the NGC Inclusion Criteria with respect to date, or because the guideline developer has indicated that they are no longer current. See the Guideline Archive for a complete list of all guidelines that have been withdrawn from the NGC Web site.

Please refer to NGC's FAQ page if you have additional questions about guidelines recently withdrawn.

Alzheimer's Association

  • Guideline for Alzheimer's disease management.

American Academy of Dermatology

  • Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
  • Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.

American Academy of Ophthalmology

  • Age-related macular degeneration.
  • Diabetic retinopathy.
  • Idiopathic macular hole.
  • Posterior vitreous detachment, retinal breaks, and lattice degeneration.

American Cancer Society

  • Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology.

American College of Preventive Medicine

  • Screening for prostate cancer in U.S. men: ACPM position statement on preventive practice.

American Diabetes Association

  • Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association.

American Gastroenterological Association Institute

  • American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease.

Announcements

NGC Spotlight

Visit the Guideline Matrix to filter NGC content in a variety of ways.

Revised Inclusion Criteria

NGC has revised its Inclusion Criteria! Visit our updated Inclusion Criteria page to see the new criteria and send us your comments.

Conference News

  • The Guidelines International Network North America (G-I-N NA) continues to sponsor a monthly webinar series on topics of interest to the North American guideline community. Information on upcoming webinars, as well as audio files and slides from past webinars, is available on the G-I-N Web site.

U.S. Food and Drug Administration (FDA) Advisories

  • December 3, 2013: Onfi (clobazam): FDA is warning the public that the anti-seizure drug Onfi (clobazam) can cause rare but serious skin reactions that can result in permanent harm and death. FDA approved changes to the Onfi drug label and the patient Medication Guide to describe the risk of these serious skin reactions.
  • November 25, 2013: Rosiglitazone-containing Diabetes Medicines: FDA has determined that recent data for rosiglitazone-containing drugs, such as Avandia, Avandamet, Avandaryl, and generics, do not show an increased risk of heart attack compared to the standard type 2 diabetes medicines metformin and sulfonylurea. As a result, FDA is requiring removal of the prescribing and dispensing restrictions for rosiglitazone medicines that were put in place in 2010. This decision is based on FDA review of data from a large, long-term clinical trial and is supported by a comprehensive, outside, expert re-evaluation of the data conducted by the Duke Clinical Research Institute (DCRI).
  • November 20, 2013: Lexiscan (regadenoson) and Adenoscan (adenosine): The FDA is warning health care professionals of the rare but serious risk of heart attack and death with use of the cardiac nuclear stress test agents Lexiscan (regadenoson) and Adenoscan (adenosine). FDA has approved changes to the drug labels to reflect these serious events and updated recommendations for use of these agents. The Warnings & Precautions section of the Lexiscan and Adenoscan labels previously contained information about the possible risk of heart attack and death with use of these drugs. However, recent reports of serious adverse events in the FDA Adverse Event Reporting System (FAERS) database and the medical literature prompted approval changes to the drug labels to include updated recommendations for use.
  • November 13, 2013: Over-the-Counter Topical Antiseptic Products: FDA is requesting label and packaging changes to enhance the safe use of certain over-the-counter (OTC) topical antiseptic products. The request is the result of an ongoing evaluation of infrequent but continuing reports of infections resulting from antiseptic products labeled for preoperative or preinjection skin preparation. Health care professionals and patients should follow all label directions to decrease the chances of infection.

NGC's Sister Resources